Neural Antibody Testing for Autoimmune Encephalitis: A Canadian Single-Centre Experience

Adrian Budhram, Ario Mirian, Sean McFadden, Pamela Edmond, Vipin Bhayana, Liju Yang

ABSTRACT: Neural antibodies have emerged as useful biomarkers in suspected autoimmune encephalitis. We reviewed results of neural antibody testing (anti-N-methyl D-aspartate receptor (NMDAR), leucine-rich glioma-inactivated protein (LG11), contactin-associated protein-like 2 (CASPR2), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA), γ-aminobutyric acid type B receptor (GABA(B)R), dipeptidyl-peptidase-like protein-6 (DPPX), IgLON family member 5 (IgLON5) and glutamic acid decarboxylase-65 (GAD65)) using cell-based assays (CBAs) and tissue indirect immunofluorescence (TIIF) at our centre. Our findings suggest increased clinical sensitivity of CBA compared to TIIF. However, this may come at some expense to clinical specificity, as evidenced by possible false-positive results when weak serum positivity by CBA was observed for certain antibodies (i.e. anti-NMDAR, CASPR2). In such cases, correlation with serum TIIF, as well as CSF CBA and TIIF, aids in identifying true-positive results.

RÉSUMÉ : Utiliser des anticorps neuronaux de détection dans des cas d’encéphalite auto-immune : une expérience menée dans un établissement de santé canadien. Les anticorps neuronaux apparaissent désormais comme des biomarqueurs utiles dans des cas suspectés d’encéphalite auto-immune. Nous avons ainsi passé en revue les résultats de tests menés au moyen d’anticorps (anti-R-NMDA, anti-LG11, anti-CASPR2, anti-AMPA, anti-GABA (B) R, anti-DPPX, anti-IgLON5 et anti-GAD65) en faisant appel, au sein de notre établissement, à des essais cellulaires (cell-based assays) et à la technique d’immunofluorescence indirecte des tissus (TIIFT). À cet égard, nos observations suggèrent une sensibilité clinique accrue des essais cellulaires en comparaison avec la TIIFT. Il est néanmoins possible que cela se produise au détriment de la spécificité clinique comme en témoignent de possibles résultats faussement positifs lorsqu’une faible positivité du sérum a été observée pour certains anticorps (par exemple l’anti-NMDAR, l’anti-CASPR2) lors d’essais cellulaires. Dans de tels cas, une corrélation établie avec le sérum de la TIIFT, de même qu’avec les essais cellulaires et la TIIFT du liquide céphalo-rachidien (LCR), a permis d’identifier des résultats réellement positifs.

Keywords: Autoimmune disease, Neuroimmunology, Encephalitis, Neural antibody
doi:10.1017/cjn.2021.23

In recent decades, antibodies targeting intracellular, cell surface and synaptic neural antigens have emerged as biomarkers that aid in the diagnosis of autoimmune encephalitis.¹ Many of these neural antibodies are detected using brain tissue indirect immunofluorescence (TIIF) to identify characteristic staining patterns, followed by a second assay to confirm antibody specificity. Detection of antibodies against intracellular neural antigens, including well-characterised paraneoplastic or “onconeural” antibodies (anti-Hu, Yo, amphiphysin, CV2/collapsin response mediator protein 5 (CRMP5) and Ma2), typically does not require that the target antigen be in its native conformation, permitting the use of Western blot/line immunoblot (WB/LIB) as a second confirmatory assay alongside TIIF.² In contrast, detection of antibodies against extracellular cell surface/synaptic antigens typically requires that critical epitopes remain in their native conformation, leading to the use of transacted cell-based assays (CBAs) expressing the antigen of interest on their surface as a second confirmatory assay alongside TIIF.³

Testing for neural antibodies has historically been performed by a small number of reference laboratories with dedicated expertise in this area. In recent years, however, the advent of commercialised assays has afforded laboratories with an interest in autoimmune neurology the opportunity to offer neural antibody testing, which has the advantage of reduced cost and improved turnaround times compared to send out testing. Due to relative ease of test implementation and interpretation of WB/LIB and CBA compared to TIIF, some laboratories have opted to offer stand-alone commercial assays that were initially described as confirmatory (i.e. WB/LIB, CBA) without TIIF for neural antibody detection. Studies validating this approach to neural antibody testing in clinical practice, however, are lacking, and indeterminate results of uncertain clinical significance have been reported.³ We previously demonstrated that the positive

From the Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada (AB, AM); Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, Canada (AB, PE, VB, LY); and EUROIMMUN Medical Diagnostics Canada Inc., Mississauga, Ontario, Canada (SMF)

Correspondence to: Adrian Budhram, University Hospital, Department of Clinical Neurological Sciences, 339 Windermere Rd., London, Ontario N6A 5A5, Canada. Email: adrian.budhram@lhsc.on.ca

https://doi.org/10.1017/cjn.2021.23 Published online by Cambridge University Press
predictive value of onconeural antibody testing for paraneoplastic neurological syndromes (PNS) to be only 39% when reporting commercial LIB positivity alone without TIIF. Our findings highlighted that while commercial LIB is a useful confirmatory assay when TIIF staining is concerning for a particular onconeural antibody, its use as a stand-alone assay may lead to a high number of false-positive results. In order to offer neural antibody testing for autoimmune encephalitis, we introduced a panel of CBAs for the detection of neural antibodies against extracellular cell surface/synaptic antigens (N-methyl-D-aspartate receptor (NMDAR), leucine-rich glioma-inactivated protein 1 (LGI1), contactin-associated protein-like 2 (CASPR2), α-aminobutyric acid type B receptor (GABA_B)R, γ-aminobutyric acid type B receptor (GABA_A)R, dipeptidyl-peptidase-like protein-6 (DPPX), IgLON family member 5 (IgLON5)) as well as the intracellular synaptic antigen glutamic acid decarboxylase-65 (GAD65), performed in parallel with TIIF. Similar to our examination of onconeural antibody testing, we reviewed the results of our autoimmune encephalitis panel after its first year of implementation with the primary aim of identifying possible false-positive results for quality assurance. As per our institutional research ethics board, quality assurance and quality improvement studies do not fall within the scope of institutional ethical review under Article 2.5 of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2), but all Pathology and Laboratory Medicine quality assurance/quality improvement studies are still reviewed departmentally to address any ethical issues that may arise.

Between March 2019 and March 2020, we received serum and/or CSF samples from 373 patients for autoimmune encephalitis antibody testing. All samples were tested in parallel by rodent hippocampus and cerebellum TIIF (EUROIMMUN, Order No. FA111 m-1005-3) as well as fixed CBA (EUROIMMUN, Order No. FA112d-1005-6, FA112d-1010-6, FA 1022-1005-50, FA1151-1005-50) for eight neural antibodies (anti-NMDAR, LGI1, CASPR2, AMPAR, GABA(B)R, DPPX, IgLON5 and GAD65) using the manufacturer’s instructions. Testing was performed at a 1:10 dilution for serum and undiluted for CSF. Samples were processed using the automated immunoassay analyzer (IF Sprinter, EUROIMMUN). A weakly positive or positive CBA, with or without corresponding TIIF positivity, was required for a positive result to be reported (automated microscopy by EUROPattern, EUROIMMUN). TIIF and CBA were each reported as negative, weakly positive or positive based on independent interpretation by two readers with experience in indirect immunofluorescence (P.E. and L.Y.). In cases with uncertainty regarding positive staining, images taken by automated microscopy were submitted to the assay manufacturer (EUROIMMUN) for additional review with discussion to achieve consensus. “Weakly positive” referred to staining that was faint, but of sufficient intensity above the background to be possibly indicative of a positive result (see Figure 1); the distinction between “weakly positive” and “positive”, while subjective, reflects potential challenges of indirect immunofluorescence interpretation in clinical practice. A clinical questionnaire containing pertinent clinical information was requested with each patient sample, to allow for clinical–serological correlation and identification of potential false-positive results as a quality assurance measure (see Supplementary document).

Over this 1-year period, 20/373 patients (5.4%) had a positive neural antibody reported (see Figure 2). Thirteen out of the 20 had only serum submitted, 1/20 had only CSF submitted and 6/20 had both serum and CSF submitted. Positive results consisted of anti-CASPR2 (6/20), NMDAR (5/20), LGI1 (4/20), GAD65 (4/20) and GABA(B)R (1/20). No sample tested positive for more than one analyte. Clinical information provided for these 20 patients to aid in clinical–serological correlation as a quality assurance measure was reviewed by a neurology resident and a neurologist with subspecialty training in Autoimmune Neurology (A.M. and A.B.). Those with a compatible clinical phenotype based on the available literature and no more likely alternative diagnosis were classified as true positives, while all other patients were flagged as possible false positives (see Table 1).

Amongst antibody-positive patients, all patients with anti-LGI1, GAD65 or GABA(B)R positivity were classified as true positives. All four patients with anti-LGI1 positivity had new-onset focal seizures, three of whom had faciobrachial dystonic seizures. Three out of the four were positive in serum by CBA (no CSF testing was performed), and 1/4 was positive in CSF by CBA (no serum testing was performed). Only 2/4 patients were positive for anti-LGI by TIIF (one serum, one CSF). Amongst four patients with anti-GAD65 positivity, two had chronic temporal lobe epilepsy, and two had a clinical/radiographic presentation concerning for autoimmune limbic encephalitis. All four patients were positive for anti-GAD65 in serum by CBA and TIIF. Two out of the four underwent CSF testing; both were positive for anti-GAD65 by CBA in CSF, and 1/2 was positive for anti-GAD65 by TIIF in CSF. The patient with anti-GABA(B)R positivity had a clinical/radiographic...
presentation concerning for autoimmune limbic encephalitis. Serum was positive for anti-GABA(B)R by CBA but not TIIF, while CSF was positive for anti-GABA(B)R by CBA and TIIF.

In contrast, only 3/6 patients with anti-CASPR2 positivity were classified as true positives; 2/3 had new-onset temporal lobe epilepsy, and 1/3 had cognitive decline with neuropathic pain. All three patients were positive for anti-CASPR2 in serum by CBA (2/3 with weakly positive staining); none were positive by TIIF in serum and none had CSF testing performed. The remaining 3/6 patients with anti-CASPR2 positivity (all serum samples, all only weakly positive by CBA) were flagged as possible false-positive results (see Table 1). None were positive for anti-CASPR2 by TIIF in serum; 1/3 underwent CSF testing that was negative for anti-CASPR2 by CBA and TIIF. Similarly, amongst patients with anti-NMDAR positivity, only 3/5 were classified as true positives; all three had a subacute neuropsychiatric syndrome with psychosis, dysautonomia, dyskinesias, seizures and/or memory impairment. Two out of the three patients were positive for anti-NMDAR in CSF by CBA and TIIF (see text). The remaining 2/5 patients with anti-NMDAR positivity (both serum samples, both only

<table>
<thead>
<tr>
<th>AMPAR = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CASPR2 = contactin-associated protein-like 2; CSF = cerebrospinal fluid; DPPX = dipeptidyl-peptidase-like protein-6; GABA&lt;sub&gt;B&lt;/sub&gt;R = γ-aminobutyric acid type B receptor; GAD65 = glutamic acid decarboxylase-65; IgLON5 = IgLON family member 5; LGI1 = leucine-rich glioma-inactivated protein 1; NMDAR = N-methyl-D-aspartate receptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>aNegative TIIF refers to negative staining for anti-NMDAR, LGI1, CASPR2, AMPAR, GABA&lt;sub&gt;B&lt;/sub&gt;R, DPPX, IgLON5 or GAD65</td>
</tr>
<tr>
<td>bPositive TIIF refers to positive staining for anti-NMDAR, LGI1, CASPR2, AMPAR, GABA&lt;sub&gt;B&lt;/sub&gt;R, DPPX, IgLON5 or GAD65</td>
</tr>
<tr>
<td>cOne patient who was positive for anti-GAD65 in serum by CBA and TIIF was positive for anti-GAD65 in CSF by CBA only (see text)</td>
</tr>
<tr>
<td>dOne patient who was negative for anti-NMDAR in serum by CBA and TIIF was positive for anti-NMDAR in CSF by CBA and TIIF (see text)</td>
</tr>
<tr>
<td>eOne patient who was positive for anti-GABABR in CSF by CBA and TIIF was positive in serum for anti-GABABR by CBA only (see text)</td>
</tr>
</tbody>
</table>

Figure 2: Flow diagram depicting classification of patients with true-positive versus false-positive autoimmune encephalitis antibody testing.
In such cases, we recommend CSF evaluation. Newer commercial qualitative assays such as CBA usually indicate high levels of anti-GAD65 if positive, in keeping with our findings of a clinically relevant neurological syndrome amongst all four patients with anti-GAD65 positivity by this methodology.7 Across all neural antibodies, no patient with a possible false-positive serum result by CBA had corresponding serum positivity by TIIF, or CSF positivity by CBA or TIIF; the presence of either is thus likely indicative of a true-positive serum CBA result, and submission of both serum and CSF to maximise diagnostic accuracy of neural antibody testing is generally recommended.

This quality assurance evaluation of neural antibody testing for suspected autoimmune encephalitis by CBA aligns with the published experiences of leading international laboratories,7,9,10 indicating appropriate neural antibody test implementation and interpretation locally. Limitations include the retrospective nature of this single-centre experience performed as a quality assurance measure, lack of extensive clinical information or comparison assays as this is not part of our routine laboratory reporting practice, and the relatively small number of positive results. Prospective, multicentre studies are needed to fully delineate the clinical and serological findings of patients with suspected autoimmune encephalitis in Canada. Nonetheless, our findings have clear clinical relevance to Canadian neurologists who order this

![Table 1: Possible false-positive results in patients undergoing neural antibody testing for suspected autoimmune encephalitis](https://doi.org/10.1017/cjn.2021.23)
testing, and can aid laboratories in optimising the diagnostic accuracy of neural antibody testing offered locally.

**ACKNOWLEDGEMENTS**

The authors would like to acknowledge Dominik Jaeger and Erik Lattwein for their review of the manuscript.

**FUNDING**

The authors acknowledge the generous financial assistance by EUROIMMUN Medical Diagnostics in the initial implementation of neural antibody testing for autoimmune encephalitis at the London Health Sciences Centre, which was provided as part of a quality assurance initiative to improve neural antibody testing in patients with suspected autoimmune encephalitis. No funding was provided for this submission.

**CONFLICT OF INTEREST**

Sean McFadden is a EUROIMMUN Medical Diagnostics Employee, but was not involved in the clinical-serological correlation of neural antibody results. The other authors have no disclosures to report.

**STATEMENT OF AUTHORSHIP**

AB is a Neurologist and Assistant Professor of Neurology who analysed the data and drafted the manuscript. AM is a Neurology Resident who analysed the data and reviewed the manuscript for intellectual content. SM is a EUROIMMUN Medical Diagnostics Employee who reviewed the manuscript for intellectual content. PE is a Senior Laboratory Technologist in the Clinical Immunology Laboratory who analysed the data and reviewed the manuscript for intellectual content.

**SUPPLEMENTARY MATERIAL**

To view supplementary material for this article, please visit https://doi.org/10.1017/cjn.2021.23.

**REFERENCES**